| Heading: |
Drugs: Prices |
| Question ID: |
1805782 |
| UIN: |
54542 |
| House: |
Commons |
| Date tabled: |
2025-05-22 |
| Asking Member ID: |
5312 |
| Asking Member display name: |
Sadik Al-Hassan
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Sadik Al-Hassan
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, how many commercial agreements NHS England has made with manufacturers of medicines which have r resulted in indication-specific pricing between January 2020 and March 2025; and what therapeutic ar |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-18 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
Information provided by NHS England shows that there have been 74 commercial agreements involving indication-specific pricing arrangements between January 2020 and March 2025. The following table shows the split by therapeutic areas:Cancer62Haematology5Ot... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |